Australia is anticipating the availability of Retatrutide, a novel medication from Novo Nordisk. This dual-action drug, targeting both GLP-1 and GIP receptors, has shown significant efficacy in clinical trials, https://thebookmarkfree.com/story22064257/retatrutide-australia-a-potential-solution-for-weight-management